Patient experiences with originator biologicals and biosimilars. Part II: a survey among users

Duration: December 2016 - March 2018

TNF-alpha inhibitors are biologicals prescribed for e.g. rheumatism, Crohn's disease, psoriasis and ulcerative colitis. The active substance of biosimilars is equal to that of the originator product. However, due to the complex nature of these drugs and the production methods used differences may occur which may result in (perceived) difference in efficacy and safety. Little is known about patient experiences with biologics and biosimilars.

How do patients experience their use of a biological or biosimilar medicine and the care they receive, and what do they consider important aspects of this care?
- Additional research question for patients who switched from biological to biosimilar: How do patients experience the care they receive when switching from an originator biological to a biosimilar, and how does this care meets their preferences and needs?
- Additional research question for patients using a biological: How do patients using an originator biological evaluate a possible switch to a biosimilar, and what are their preferences and expectations regarding the care they need when switching?

Cross-sectional survey among three groups of biological and biosimilar users:
1) Users of the originator biological;
2) Naive users of a biosimilar;
3) Switchers from an originator biological to a biosimilar

This study provides valuable insight into patients’ experiences with biological and biosimilar use, and their needs and preferences with the care they receive. Specific attention is paid to patients’ perspective on a potential switch from a biological to a biosimilar, which could assist clinical practice in their decision-making.